Featured in Vitiligo
Vitiligo News & Research
Is Ritlecitinib Effective, Tolerated for Active Nonsegmental Vitiligo?
Significant differences seen from placebo in percentage change from baseline in the Facial-Vitiligo Area Scoring Index for 50, 30 mg ritlecitinib
By Dermsquared Editorial Team | November 30, 2022
FDA Approves First Topical Treatment for Vitiligo
Opzelura can be used twice daily in patients ages 12 years and older
By Physician’s Briefing Staff | July 20, 2022